Wells Fargo analyst Larry Biegelsen initiated coverage of Kestra Medical (KMTS) with an Overweight rating and $28 price target The firm says its survey of 50 cardiologists implies faster wearable cardioverter defibrillator market growth than forecasted and greater share gains for Kestra. The company’s Assure ranked well relative to LifeVest on many key attributes, and 70% of respondents surveyed use or plan to use Assure, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical initiated with a Buy at Stifel
- Kestra Medical initiated with an Overweight at Piper Sandler
- Kestra Medical Technologies: Positioned for Growth with Next-Gen Wearable Cardioverter Defibrillator
- Buy Rating for Kestra Medical Technologies Ltd. Driven by Strong Growth Prospects and Strategic Market Positioning
- Kestra Medical initiated with a Neutral at Goldman Sachs